What does Delta-Fly Pharma, Inc. do?
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase 1/2 clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase…
What is Delta-Fly Pharma, Inc.'s P/E and P/B ratio?
Delta-Fly Pharma, Inc. has a P/E ratio of -0.5 and a P/B ratio of 30.98.
What is Delta-Fly Pharma, Inc.'s debt-to-equity ratio?
Delta-Fly Pharma, Inc. has a debt-to-equity ratio of 0.00.
How much does Delta-Fly Pharma, Inc. owe compared with what it owns?
Delta-Fly Pharma, Inc. owes ¥0.86 for every ¥1 it owns (balance sheet Mar 2026), which is high.
What is Delta-Fly Pharma, Inc.'s Positivity rank?
Delta-Fly Pharma, Inc. is ranked #10,057 of 10,750 companies globally and #3,640 of 3,683 in Japan on PositoAI, with a Positivity Score of 7,693.
Does Delta-Fly Pharma, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
Red flags (PosiRed) are not checked yet for companies in this market on PositoAI, so no result is shown for Delta-Fly Pharma, Inc..
Where can I read the latest news about Delta-Fly Pharma, Inc.?
Recent headlines about Delta-Fly Pharma, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Delta-Fly Pharma, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Delta-Fly Pharma, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.